- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| TEVOGEN Aktie jetzt für 0€ handeln | |||||
| 29.07. | Tevogen Bio becomes Tevogen Inc. | 5 | Seeking Alpha | ||
| 14.07. | Tevogen Bio Inc: Tevogen Bio Announces 2026 Annual Meeting of Stockholders | 1 | GlobeNewswire (USA) | ||
| 10.07. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.06. | Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative | 624 | GlobeNewswire (Europe) | William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 28.05. | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | 675 | GlobeNewswire (Europe) | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| 21.05. | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 531 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 20.05. | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| 18.05. | Tevogen reports reduced operating losses in 2025 and Q1 2026 | 1 | Investing.com | ||
| 18.05. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 181 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 15.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 335 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 30.04. | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 22.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 377 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| 25.03. | Tevogen Bio erfüllt nach Aktienzusammenlegung wieder Nasdaq-Anforderungen | 3 | Investing.com Deutsch | ||
| 25.03. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Tevogen Bio Inc: Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement | 281 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization | 447 | GlobeNewswire (Europe) | Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,405 | -3,09 % | Qiagen: Jonathan Pratt übernimmt den Vorstandsvorsitz | Qiagen bekommt zum 1. September 2026 einen neuen Vorstandschef. Jonathan M. Pratt übernimmt den Posten von Thierry Bernard, der als CEO und Geschäftsführer zurücktritt und den Übergang noch bis zum... ► Artikel lesen | |
| VALNEVA | 2,837 | -3,80 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
21.08.2026 / 10:04 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| AMGEN | 378,70 | +0,64 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| NOVAVAX | 7,440 | -3,00 % | Short-Squeeze, Übernahme-Poker und Militär-Vertrag - Warum Novavax, Commerzbank und HPQ Silicon jetzt die Märkte elektrisieren könnten! | 3 Aktien - 3 Chancen: Während Novavax dank des Branchenkollegen Moderna und hoher Leerverkaufsquote auf einen möglichen Short-Squeeze hoffen kann, bahnt sich bei der Commerzbank im Milliardenpoker mit... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,690 | -6,47 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 706,70 | -1,04 % | Dividendenbekanntmachungen (18.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ATKORE INC US0476491081 0,33 USD 0,285 EUR AVISTA CORPORATION US05379B1070 0,4925 USD 0,4253 EUR BWX TECHNOLOGIES INC US05605H1005 0... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,043 | +2,76 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,390 | -9,48 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,115 | -1,33 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 56,00 | -1,96 % | BioMarin Pharmaceutical Inc.: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones
Alesta to spin out all non-ALE1 assets... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,000 | -0,62 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ARROWHEAD PHARMACEUTICALS | 73,62 | -1,34 % | Arrowhead Pharmaceuticals, Inc.: People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO (plozasiran) as a New Treatment Option to Reduce Triglycerides | REDEMPLO (plozasiran) is listed in the Lauer-Taxe database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,180 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 | King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based... ► Artikel lesen | |
| TRAWS PHARMA | 0,540 | +1,92 % | Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones |
TEVOGEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,89 % bei einem Aktienkurs von 6,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN INC finden Sie auf Wallstreet Online.